openPR Logo
Press release

Alpha-Antitrypsin Deficiency Market 2017 – Global Industry Size, Share, Analysis, Trend & Future Strategic Planning

08-24-2017 12:14 PM CET | Health & Medicine

Press release from: Reports Monitor

Reports Monitor

Reports Monitor

Alpha-Antitrypsin Deficiency Market

Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2017

Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2017, provides an overview of the Alpha- Antitrypsin Deficiency (Genetic Disorders) pipeline landscape.

Alpha-antitrypsin deficiency is an inherited disease that occurs due to lack of alpha-1 antitrypsin (AAT), a protein that protects the lungs. Symptoms include shortness of breath and wheezing, lung infections, rapid heartbeat, weight loss and vision problems. Predisposing factors include smoking, exposure to dust, chemical fumes and infections.

Browse Full Table of Contents and Report Description @ www.reportsmonitor.com/alpha-antitrypsin-deficiency-pipel...

Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Alpha- Antitrypsin Deficiency (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Alpha- Antitrypsin Deficiency (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Alpha- Antitrypsin Deficiency and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 4, 2, 9 and 5 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Alpha- Antitrypsin Deficiency (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Alpha- Antitrypsin Deficiency (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Alpha- Antitrypsin Deficiency (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Alpha- Antitrypsin Deficiency (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Alpha- Antitrypsin Deficiency (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Alpha- Antitrypsin Deficiency (Genetic Disorders)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Alpha- Antitrypsin Deficiency (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Alpha- Antitrypsin Deficiency (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

For Requesting a Sample Copy of This Report, Please Visit @ goo.gl/jTFgpb

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Alpha- Antitrypsin Deficiency – Overview 6
Alpha- Antitrypsin Deficiency – Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Pipeline by Universities/Institutes 10
Products under Development by Companies 11
Products under Development by Universities/Institutes 13
Alpha- Antitrypsin Deficiency – Therapeutics Assessment 14
Assessment by Target 14
Assessment by Mechanism of Action 16
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Alpha- Antitrypsin Deficiency – Companies Involved in Therapeutics Development 22
Adverum Biotechnologies Inc 22
Alnylam Pharmaceuticals Inc 22
Applied Genetic Technologies Corp 23
Arrowhead Pharmaceuticals Inc 23
Carolus Therapeutics Inc 24
Cevec Pharmaceuticals GmbH 24
Editas Medicine Inc 25
Grifols SA 25
Inhibrx LP 26
Intellia Therapeutics Inc 26
International Stem Cell Corp 27
Kamada Ltd 27
OncBioMune Pharmaceuticals Inc 28
Polyphor Ltd 28
ProMetic Life Sciences Inc 29
rEVO Biologics Inc 29
Z Factor Ltd 30
Alpha- Antitrypsin Deficiency – Drug Profiles 31
ADVM-043 – Drug Profile 31
AGTC-0106 – Drug Profile 33
ALN-AAT – Drug Profile 35
ALNAAT-02 – Drug Profile 38
alpha-1 proteinase inhibitor (human) – Drug Profile 39
alpha-1 proteinase inhibitor (human) second generation – Drug Profile 40
alpha-1 proteinase inhibitor (recombinant) – Drug Profile 44
ARC-AAT – Drug Profile 46
ARO-AAT – Drug Profile 50
CT-2009 – Drug Profile 51
Drug for Chronic Obstructive Pulmonary Disease and Alpha-1 Antitrypsin Deficiency – Drug Profile 52
Gene Therapy for Alpha-1 Antitrypsin Deficiency – Drug Profile 53
Oligonucleotides to Activate Alpha-1 Antitrypsin for Alpha-Antitrypsin Deficiency – Drug Profile 54
Oligonucleotides to Inhibit Alpha-1 Antitrypsin for Alpha-Antitrypsin Deficiency – Drug Profile 55
POL-6014 – Drug Profile 56
rAAV2-CB-hAAT – Drug Profile 58
Recombinant Human Alpha-1 Antitrypsin – Drug Profile 59
Recombinant Human Alpha-1 Antitrypsin Replacement for Alpha-Antitrypsin Deficiency – Drug Profile 60
Recombinant Protein for Alpha-1 Antitrypsin Deficiency – Drug Profile 61
Small Molecules for Alpha-1 Antitrypsin Deficiency – Drug Profile 62
Small Molecules to Activate SERPINA1 for Alpha-1 Antitrypsin Deficiency – Drug Profile 63
Small Molecules to Inhibit Alpha-1 Antitrypsin Polymerization for Alpha-1 Antitrypsin Deficiency – Drug Profile 64
Stem Cell Therapy for Alpha-Antitrypsin Deficiency, Crigler-Najjar Syndrome and Liver Cirrhosis – Drug Profile 65
Alpha- Antitrypsin Deficiency – Dormant Projects 66
Alpha- Antitrypsin Deficiency – Discontinued Products 67
Alpha- Antitrypsin Deficiency – Product Development Milestones 68
Featured News & Press Releases 68
Appendix 80
Methodology 80
Coverage 80
Secondary Research 80
Primary Research 80
Expert Panel Validation 80
Contact Us 80
Disclaimer 81

About Us
Reports Monitor (ReportsMonitor.com) is a platform to meet the market research and business intelligence requirements. Our aim is to change the dynamics of the Market Research industry by providing quality intelligence backed by data. Your requirement for market forecasting is fulfilled by our exclusive quantitative and analytics driven intelligence. We have a vast collection of reports, covering maximum industries worldwide. Our process is meticulously planned and executed in order to use maximum resources and explore the market for getting genuine insights. Decision makers can now rely on our distinct data gathering methods to get factual market forecasting and detailed analysis.

Contact Us
Jay Matthews
Direct: +1 513 549-5911
Email: sales@reportsmonitor.com
Website: www.reportsmonitor.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Alpha-Antitrypsin Deficiency Market 2017 – Global Industry Size, Share, Analysis, Trend & Future Strategic Planning here

News-ID: 683600 • Views: 135

More Releases from Reports Monitor

2019 Global Smart Home Security and Safety Systems Market Trend Analysis and Ind …
Smart Home Security and Safety Systems Market GMD analysis model indicates that the aggregated revenue of global smart home security & safety systems market during 2019-2025 is expected to reach $134.5 billion owing to growing adoption of various types of smart security devices in global households. Have Questions? Request a sample or make an Inquiry before buying this report by clicking the link below:- www.reportsmonitor.com/request_sample/352365 Scope of the Report: Highlighted with 72
Radar Sensor Market 2019 Top Key Players: NXP Semiconductors N.V., Robert Bosch …
Radar Sensor Market The report provides a global analysis of Radar Sensor Market data from 2019 to 2024. The report reveals the overview, chain structure, and illustrate the industry’s current situation, evaluate global market volume/share. The market report studies key player’s Profiles/Analysis, product insights, regional analysis insights, product types, and product application insights. The market has been qualified based on a comprehensive market analysis with inputs from industry experts. Have Questions?
OKR Software Market report with Leading players: SpiraLinks, Wrike, BetterWorks, …
2019-2025 OKR Software Market Report with Depth Analysis: The report provides a global analysis of the OKR Software Market report provides Insightful information to the clients enhancing their basic leadership capacity identified. This Report is segmented into Manufactures, Types, Applications, and Regions. The market covers the wide spectrum of the factors governing future growth, including drivers, challenges, emerging trends, technology changes, and environmental factors. The global OKR Software market size was xx million US$
Event Logistics Market analysis report with Major players Rhenus Logistics, UPS, …
Event Logistics Market Market Overview of Event Logistics Market: The report provides a global analysis of Event Logistics Market Report provides Insightful information to the clients enhancing their basic leadership capacity identified. This Report is segmented into Manufactures, Types, Applications, and Regions. The market covers the wide spectrum of the factors governing future growth including drivers, challenges, emerging trends, technology changes, and environmental factors. The global Event Logistics market size was xx

All 10163 Releases


More Releases for Antitrypsin

Global Alpha-Antitrypsin Deficiency Treatment Market Expected to Recover during …
Market Research Hub (MRH) has recently broadcasted a new study to its broad research portfolio, which is titled as “Global Alpha-Antitrypsin Deficiency Treatment Market Research Report 2018” provides an in-depth analysis of the Alpha-Antitrypsin Deficiency Treatment with the forecast of market size and growth. The analysis includes addressable market, market by volume, market share by business type and by segment (external and in-house).The research study examines the "keyword" on the
Global Alpha 1 Antitrypsin Deficiency Treatment Market Worth of US$2,908.1 Milli …
Market Research Reports Search Engine (MRRSE) has been serving as an active source to cater intelligent research report to enlighten both readers and investors. This research study titled “Alpha 1 Antitrypsin Deficiency Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 – 2025” Click here for Free Sample Report @ https://www.mrrse.com/sample/3347 The demand in the global alpha-1 antitrypsin deficiency treatment market is projected to increment at an admirable
Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2017
ReportsWorldwide has announced the addition of a new report title Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2017, provides an overview of the Alpha- Antitrypsin Deficiency (Genetic Disorders) pipeline landscape. Alpha-antitrypsin deficiency is an inherited disease that occurs due to lack of alpha-1 antitrypsin (AAT),
Alpha - Antitrypsin Deficiency - Pipeline Review, H1 Pharmaceutical Research Rep …
Market Research Hub (MRH) has recently publicized a new study to its vast repository, which is titled as “Alpha - Antitrypsin Deficiency - Pipeline Review, H1 2016”. The report provides comprehensive information on the therapeutics under development for Alpha- Antitrypsin Deficiency, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. Request For Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=713857 The report also covers the descriptive pharmacological
Alpha- Antitrypsin Deficiency - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Alpha- Antitrypsin Deficiency - Pipeline Review, H1 2017 to its growing collection of premium market research reports. Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alpha- Antitrypsin Deficiency - Pipeline Review, H1 2017, provides an overview of the Alpha- Antitrypsin Deficiency (Genetic Disorders) pipeline landscape. Alpha-antitrypsin deficiency is an inherited disease that occurs due to lack of alpha-1 antitrypsin (AAT),
Alpha - Antitrypsin Deficiency - Pipeline Review 2016 | Market Research Report
Researchmoz added Most up-to-date research on "Alpha - Antitrypsin Deficiency - Pipeline Review, H1 2016" to its huge collection of research reports. Alpha- Antitrypsin Deficiency - Pipeline Review, H1 2016, provides an overview of the Alpha- Antitrypsin Deficiency pipeline landscape. The report provides comprehensive information on the therapeutics under development for Alpha- Antitrypsin Deficiency, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and